Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension
- PMID: 9797181
- DOI: 10.1097/00004872-199816050-00017
Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension
Abstract
Objective: To compare the effects of a calcium antagonist (nitrendipine) and an angiotensin converting enzyme inhibitor (enalapril) with those of placebo on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension.
Design: A double-blind randomized, placebo-controlled trial.
Setting: General practitioners referred patients to the trial physician.
Patients: The study population comprised 121 patients with non-insulin-dependent diabetes mellitus. Inclusion criteria for blood pressure were diastolic blood pressure 90-115 mmHg and systolic blood pressure < or = 200 mmHg, while subjects were not being administered blood-pressure-lowering drugs for 3 weeks.
Intervention: Patients were randomly allocated to receive nitrendipine (n = 40), enalapril (n = 40) or placebo (n = 41). The treatment period was 48 weeks.
Main outcome measures: The effect of nitrendipine was defined as the difference in change in left ventricular mass index from baseline between nitrendipine treatment and placebo after 48 weeks of treatment. The effects of nitrendipine compared with that of enalapril and of enalapril compared with placebo were defined similarly. Left ventricular mass was measured by M-mode echocardiography.
Results: Use of nitrendipine and enalapril led to significant and almost identical reductions in systolic and diastolic blood pressures. During 48 weeks left ventricular mass index decreased by 5% for patients in the nitrendipine group (decrease by 12 g/m2, 95% confidence interval 1-23), remained about the same for patients in the enalapril group (decrease by 1 g/m2, 95% confidence interval decrease by 10 to increase by 9) and increased by 9% for patients in the placebo group (increase by 9 g/m2, 95% confidence interval 2-16).
Conclusion: These results indicate that administration of nitrendipine to patients with non-insulin-dependent diabetes mellitus and hypertension reduces left ventricular mass index. Enalapril appears not to induce regression, but perhaps prevents progression with an effect that is intermediate between those of nitrendipine and placebo.
Similar articles
-
Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.Drugs. 2004;64(10):1135-48. doi: 10.2165/00003495-200464100-00009. Drugs. 2004. PMID: 15139792 Review.
-
Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients.Diabetes Care. 1997 Aug;20(8):1290-2. doi: 10.2337/diacare.20.8.1290. Diabetes Care. 1997. PMID: 9250456 Clinical Trial.
-
Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.Clin Drug Investig. 2009;29(7):459-469. doi: 10.2165/00044011-200929070-00004. Clin Drug Investig. 2009. PMID: 19499963
-
Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design.J Cardiovasc Pharmacol. 2001 Dec;38(6):840-9. doi: 10.1097/00005344-200112000-00005. J Cardiovasc Pharmacol. 2001. PMID: 11707687 Clinical Trial.
-
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.Minerva Cardioangiol. 2002 Jun;50(3):169-74. Minerva Cardioangiol. 2002. PMID: 12107398 Review.
Cited by
-
Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria.Eur J Clin Pharmacol. 2005 Aug;61(7):483-90. doi: 10.1007/s00228-005-0961-2. Epub 2005 Jul 15. Eur J Clin Pharmacol. 2005. PMID: 16021438 Clinical Trial.
-
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170. doi: 10.1002/14651858.CD008170.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Jul 13;7:CD008161. doi: 10.1002/14651858.CD008161.pub3. PMID: 30480768 Free PMC article. Updated.
-
Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).Circulation. 2017 Aug 1;136(5):440-450. doi: 10.1161/CIRCULATIONAHA.117.028441. Epub 2017 May 16. Circulation. 2017. PMID: 28512184 Free PMC article. Clinical Trial.
-
Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.Drugs. 2004;64(10):1135-48. doi: 10.2165/00003495-200464100-00009. Drugs. 2004. PMID: 15139792 Review.
-
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical